Investor Overview

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

(Common)
Price	Change	% Change	Volume

Previous Close	Today's Open	Intraday High	Intraday Low

Exchange: (US Dollar)
Jun 4, 2020 6:41 AM EDT

Date	Title
05/08/20	AtriCure CONVERGE Investor Presentation in Conjunction with HRS 2.9 MB
04/29/20	Investor Presentation 1.6 MB
04/29/20	2019 Annual Report 1.9 MB
08/12/19	Acquisition of SentreHEART Overview 778.9 KB

Date	Title
05/11/20	AtriCure Announces Pricing of Public Offering of Common Stock MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to
05/11/20	AtriCure Announces Proposed Public Offering of Common Stock MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell
05/08/20	AtriCure Announces Results from CONVERGE IDE Clinical Trial Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure MASON, Ohio --(BUSINESS WIRE)--May 8, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)
04/30/20	AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting MASON, Ohio --(BUSINESS WIRE)--Apr. 30, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m.

Date	Title
05/11/20	AtriCure Announces Pricing of Public Offering of Common Stock MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to
05/11/20	AtriCure Announces Proposed Public Offering of Common Stock MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell
05/08/20	AtriCure Announces Results from CONVERGE IDE Clinical Trial Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure MASON, Ohio --(BUSINESS WIRE)--May 8, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)
04/30/20	AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting MASON, Ohio --(BUSINESS WIRE)--Apr. 30, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m.

More National News >>

Date	Title
08/13/19	AtriCure Completes Acquisition of SentreHEART MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
08/28/18	AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.
06/05/18	AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...
04/25/17	AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it

More International News >>